Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Sangamo Therapeutics's operating margin for the twelve months ending Mar 31, 2026 was -357.5%. For fiscal 2025 it was -306.5%, against -179.9% the year before. The highest annual figure on record is -58.4% in fiscal 2014.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -306.5% | −126.7 |
| FY2024 | Dec 31, 2024 | -179.9% | −24.4 |
| FY2023 | Dec 31, 2023 | -155.5% | +25.4 |
| FY2022 | Dec 31, 2022 | -180.8% | −15.2 |
| FY2021 | Dec 31, 2021 | -165.6% | −56.0 |
| FY2020 | Dec 31, 2020 | -109.6% | −6.9 |
| FY2019 | Dec 31, 2019 | -102.7% | −11.3 |
| FY2018 | Dec 31, 2018 | -91.4% | +62.8 |
| FY2017 | Dec 31, 2017 | -154.1% | +220.1 |
| FY2016 | Dec 31, 2016 | -374.2% | −255.7 |
| FY2015 | Dec 31, 2015 | -118.5% | −60.1 |
| FY2014 | Dec 31, 2014 | -58.4% | +52.3 |
| FY2013 | Dec 31, 2013 | -110.7% | −8.2 |
| FY2012 | Dec 31, 2012 | -102.5% | +244.6 |
| FY2011 | Dec 31, 2011 | -347.1% | −227.3 |
| FY2010 | Dec 31, 2010 | -119.9% | −32.4 |
| FY2009 | Dec 31, 2009 | -87.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -2215.4% | −1755.1 |
| Q4 FY2025 | Dec 31, 2025 | -268.5% | +75.7 |
| Q3 FY2025 | Sep 30, 2025 | -6119.3% | −6140.8 |
| Q2 FY2025 | Jun 30, 2025 | -97.5% | +10319.3 |
| Q1 FY2025 | Mar 31, 2025 | -460.3% | +10252.0 |
| Q4 FY2024 | Dec 31, 2024 | -344.2% | +2694.9 |
| Q3 FY2024 | Sep 30, 2024 | 21.5% | +1153.8 |
| Q2 FY2024 | Jun 30, 2024 | -10416.9% | −8608.9 |
| Q1 FY2024 | Mar 31, 2024 | -10712.3% | −10723.7 |
| Q4 FY2023 | Dec 31, 2023 | -3039.1% | −2835.7 |
| Q3 FY2023 | Sep 30, 2023 | -1132.2% | −924.8 |
| Q2 FY2023 | Jun 30, 2023 | -1807.9% | −1652.3 |
| Q1 FY2023 | Mar 31, 2023 | 11.4% | +171.7 |
| Q4 FY2022 | Dec 31, 2022 | -203.4% | −60.9 |
| Q3 FY2022 | Sep 30, 2022 | -207.5% | −37.9 |
| Q2 FY2022 | Jun 30, 2022 | -155.7% | +19.1 |
| Q1 FY2022 | Mar 31, 2022 | -160.3% | +15.9 |
| Q4 FY2021 | Dec 31, 2021 | -142.6% | +25.8 |
| Q3 FY2021 | Sep 30, 2021 | -169.6% | −163.2 |
| Q2 FY2021 | Jun 30, 2021 | -174.7% | +1.1 |
| Q1 FY2021 | Mar 31, 2021 | -176.2% | +164.3 |
| Q4 FY2020 | Dec 31, 2020 | -168.3% | −171.0 |
| Q3 FY2020 | Sep 30, 2020 | -6.4% | +126.8 |
| Q2 FY2020 | Jun 30, 2020 | -175.8% | +15.1 |
| Q1 FY2020 | Mar 31, 2020 | -340.5% | +203.4 |
| Q4 FY2019 | Dec 31, 2019 | 2.7% | +80.1 |
| Q3 FY2019 | Sep 30, 2019 | -133.2% | −64.3 |
| Q2 FY2019 | Jun 30, 2019 | -190.9% | −101.6 |
| Q1 FY2019 | Mar 31, 2019 | -543.9% | −377.7 |
| Q4 FY2018 | Dec 31, 2018 | -77.4% | +27.9 |
| Q3 FY2018 | Sep 30, 2018 | -68.9% | +41.4 |
| Q2 FY2018 | Jun 30, 2018 | -89.4% | +65.3 |
| Q1 FY2018 | Mar 31, 2018 | -166.2% | +324.1 |
| Q4 FY2017 | Dec 31, 2017 | -105.3% | +4.9 |
| Q3 FY2017 | Sep 30, 2017 | -110.4% | +570.0 |
| Q2 FY2017 | Jun 30, 2017 | -154.7% | +570.4 |
| Q1 FY2017 | Mar 31, 2017 | -490.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -110.2% | – |
| Q3 FY2016 | Sep 30, 2016 | -680.3% | – |
| Q2 FY2016 | Jun 30, 2016 | -725.1% | – |
See a number that looks wrong?